|
TATDN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.92439994232075E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
6.690400E-02 |
| Stage1-vs-Stage3 |
6.004100E-02 |
| Stage1-vs-Stage4 |
4.520100E-03 |
| Stage2-vs-Stage3 |
3.778400E-03 |
| Stage2-vs-Stage4 |
1.003100E-03 |
| Stage3-vs-Stage4 |
3.120000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.59390000087356E-08 |
| Normal-vs-Asian |
1.62492241884138E-12 |
| Caucasian-vs-AfricanAmerican |
1.067200E-01 |
| Caucasian-vs-Asian |
4.583200E-01 |
| AfricanAmerican-vs-Asian |
2.584000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.401200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
5.16980000031531E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.538400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.678800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.512800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.201000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.387600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.643200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.11259999999269E-05 |
| Classical-VS-Follicular |
1.963770E-01 |
| Classical-VS-Other |
3.878200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.79240000000025E-05 |
| Tall-VS-Other |
5.281800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.922400E-01 |
| Follicular-VS-Normal |
2.36666242159345E-12 |
| Other-VS-Normal |
2.9991000000118E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.986930E-04 |
|
|
